Global Multiplex Assays Market Growth Opportunities to
Dublin, Feb. 23, 2022 (GLOBE NEWSWIRE) -- The "Multiplex Assays Market by Product (Consumables, Instruments, Software & Services), Type (Nucleic...
Source: globenewswire.com
Page 5 - Scale Diagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Scale Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Scale Diagnostics Today - Breaking & Trending Today
Global Companion Diagnostics Market Share, by Product & Service, 2021 vs. 2026: Assays, Kits & Reagents Segment to Dominate Market in 2026
/PRNewswire/ -- The "Global Companion Diagnostics Market by Product,Technology, Indication, End User and Region - Forecast to 2026" report has been added to...
Source: prnewswire.com
Worldwide Multiplex Assay Industry to 2028 - by Product & Service, Type, Application. Technology, Industrial Verticals and Region
/PRNewswire/ -- The "Global Multiplex Assay Market 2021-2028" report has been added to ResearchAndMarkets.com's offering. The publisher suggests that the...
Source: prnewswire.com
Worldwide Multiplex Assay Industry to 2028 - by Product & Service, Type, Application. Technology, Industrial Verticals and Region
/PRNewswire/ -- The "Global Multiplex Assay Market 2021-2028" report has been added to ResearchAndMarkets.com's offering. The publisher suggests that the...
Source: prnewswire.com
The Worldwide Immuno-Oncology Assays Industry is Projected to Reach $7.9 Billion by 2026 at a CAGR of 12.5% from 2021
Share this article Share this article ResearchAndMarkets.com's offering. The global immuno-oncology assays market is projected to reach USD 7.9 billion by 2026 from USD 4.4 billion in 2021, at a CAGR of 12.5% during the forecast period. Market growth is driven by factors such as the growing significance of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies. On the other hand, the requirement of high capital investments and low cost-benefit ratio and the unfavorable regulatory and reimbursement scenario are the major factors hamp...
Source: prnewswire.com